Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
A technology of metformin and metformin base, which is applied in the field of metformin-releasing compositions, and can solve the problem of insufficiency
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0079] A specific example of the steps used to prepare the metformin-transport moiety complex is provided in Example 1, using Figure 4C Description, wherein the transport part is a fatty acid. Metformin base was prepared from the hydrochloride salt using the ion exchange method. The fatty acid solution is contacted with metformin base in a solvent to reform the metformin-fatty acid complex.
[0080] In Example 1, complexes are formed with lauric acid as an exemplary fatty acid transport moiety. It is understood that lauric acid is exemplary only and that the procedure for its preparation is equally applicable to other substances suitable for use as transport moieties, as well as to fatty acids of any carbon chain length. For example, metformin forms complexes with various fatty acids or salts of fatty acids, the fatty acids having 6-18 carbon atoms, more preferably 8-16 carbon atoms, even more preferably 10-14 carbon atoms. Fatty acids or salts thereof may be saturated or ...
Embodiment 4
[0136] Example 4 describes similar Figure 11 Preparation of the dosage forms shown in .
[0137] Figure 12 is a schematic diagram of another exemplary osmotic dosage form. Such dosage forms are described in detail in US Patent Nos. 4,612,008, 5,082,668, and 5,091,190, which are incorporated herein by reference. Briefly, the dosage form 40 shown in cross-section has a semi-permeable wall 42 defining an interior compartment 44 . The inner compartment 44 contains a bilayer compressed core with a drug layer 46 and a push layer 48 . As will be described below, the pusher layer 48 is a displacement displacement composition placed in the dosage form, during use the pusher layer expands and the material forming the drug layer exits the dosage form through one or more outlets such as outlet 50 . The push layer can be placed in an alignment layer in contact with the drug layer, e.g. Figure 12 Alternatively, the push layer may have one or more intermediate layers separating the p...
Embodiment 2
[0185] In vivo colonic absorption using an oral gavage rat model
[0186] Eight rats were randomly divided into two treatment groups. After a 12-24 hour fast, the first group was orally gavaged with 40 mg / kg free base equivalents of metformin hydrochloride. A second group was orally gavaged with 40 mg / kg of the free base equivalent of metformin laurate complex prepared as described in Example 1. Blood samples were collected from the tail vein at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours and 8 hours after oral gavage. Metformin plasma concentrations were analyzed by LC / MS / MS. The result is as Figure 7 shown in .
[0187] At the conclusion of the study, the rats were sacrificed and the gastrointestinal tract of the experimental animals was evaluated visually for signs of irritation. No stimulatory effect was observed in rats treated with the complex or metformin hydrochloride.
PUM
| Property | Measurement | Unit |
|---|---|---|
| Melting point | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to view more - R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap